MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8480
-0.0170
-1.97%
After Hours: 0.8200 -0.028 -3.30% 19:55 09/25 EDT
OPEN
0.8525
PREV CLOSE
0.8650
HIGH
0.8610
LOW
0.8100
VOLUME
4.27M
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.3902
MARKET CAP
110.98M
P/E (TTM)
-0.0143
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 5h ago
Sidoti: Virtual Investor Conference
* Presentation Times and Weblinks Released for Over 150 Presenting Companies * Day 1: Wednesday, September 23, 2020 * ALL INSTITUTIONAL AND RETAIL INVESTORS ARE WELCOMENEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs
ACCESSWIRE · 4d ago
Tonix Pharma Will Host Live Webinar On Thursday, Sept. 24, 2020 At 10 a.m. EDT 'Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?'
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will host a live webinar on Thursday, September 24, 2020 at 10:00 a.m. ET to
Benzinga · 09/17 13:19
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Results from COV-LOGIC Study Expected in First Half of 2021NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the observational COV-LOGIC
GlobeNewswire · 09/15 13:00
Tonix Pharmaceuticals Announces $30.0M Purchase Agreement With Lincoln Park Capital
On September 3, 2020, Tonix Pharmaceuticals Holding Corp. (the “Company”) entered into a purchase agreement, dated as of September 3, 2020 (the “Purchase Agreement with Lincoln Park Capital Fund, LLC
Benzinga · 09/04 13:05
TNXP: Interim Analysis for Phase 3 RELIEF Trial in Sep. 2020; Preclinical data for TNX-1800 in 4Q20…
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Interim Analysis for Phase 3 RELIEF Trial in Sep. 2020 In July 2020, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that the Phase 3 RELIEF trial of TNX-102 SL was fully enrolled ahead of schedule. We anticipate
Zacks Small Cap Research · 09/03 14:12
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020 Positive Outcomes in Both Trials Would Support Submission of NDA in Second Half 2022NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq
GlobeNewswire · 09/03 14:00
Tonix Pharmaceuticals Initiates Enrollment In Second Potentially Pivotal Phase 3 Study Of TNX-102 SL For Management Of Fibromylagia; Topline Results Expected In Q4 2020
Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia Interim Analysis Results from Ongoing Phase 3 RELIEF Study
Benzinga · 09/03 13:05
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TNXP. Analyze the recent business situations of Tonix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNXP stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 1.63M
% Owned: 1.25%
Shares Outstanding: 130.87M
TypeInstitutionsShares
Increased
7
439.55K
New
11
96.46K
Decreased
2
7.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/President/Director
Seth Lederman
Chief Financial Officer/Treasurer
Bradley Saenger
Chief Operating Officer
Jessica Morris
Executive Vice President
Herbert Harris
Secretary
Gregory Sullivan
Lead Director/Independent Director
James Treco
Director
Richard Bagger
Independent Director
Margaret Bell
Independent Director
Daniel Goodman
Independent Director
David Grange
Independent Director
Adeoye Olukotun
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.